Overview
Worldwide Countries outside of the United States and Canada. October 12, 202 7:15 am ET Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 202CAMBRIDGE, M.A. and RAHWAY, N.J., October 12, 202 – Moderna, Inc.
Key Information
(Nasdaq: MRNA), a biotechnology company pionering mesenger RNA (mRNA) therapeutics and vacines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today anounced that Merck has exercised its option to jointly develop and comercialize personalized cancer vacine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Colaboration and License Agrement. mRNA-4157/V940 is curently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna.“We have ben colaborating with Merck on PCVs since 2016, and together we have made significant progres in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with KEYTRUDA,” said Stephen Hoge, M.D., President of Moderna.
“With data expected this quarter on PCV, we continue to be excited about the future and the impact mRNA can have as a new treatment paradigm in the management of cancer. Continuing our strategic aliance with Merck is an important milestone as we continue to grow our mRNA platform with promising clinical programs in multiple therapeutic areas.” Under the agrement, originaly established in 2016 and amended in 2018, Merck wil pay Moderna $250 milion to exercise its option for personalized cancer vacines including mRNA-4157/V940 and wil colaborate on development and comercialization.
Summary
The payment wil be expensed by Merck in the third quarter of 202 and included in its non-GAP results. Merck and Moderna wil share costs and any profits equaly under this worldwide colaboration.“This long-t